Stockscreener 앱 받기
43.78
2.17%
-0.97
시간 외 거래:
43.78
전일 마감가:
$44.75
열려 있는:
$44.5
하루 거래량:
1.04M
Relative Volume:
1.45
시가총액:
$4.03B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-4.8807
EPS:
-8.97
순현금흐름:
$-492.48M
1주 성능:
-13.70%
1개월 성능:
-22.18%
6개월 성능:
+4.56%
1년 성능:
+9.53%
1일 변동 폭
$43.04
$44.92
1주일 범위
$43.04
$50.48
52주 변동 폭
$37.02
$60.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RARE | 43.78 | 4.03B | 522.75M | -558.99M | -492.48M | -8.97 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
State of New Jersey Common Pension Fund D Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Osteogenesis Imperfecta Treatment Market 2024-2031: Global - openPR
How To Trade (RARE) - Stock Traders Daily
RTW INVESTMENTS, LP Adjusts Stake in Ultragenyx Pharmaceutical I - GuruFocus.com
Ultragenyx Pharmaceutical's SWOT analysis: pipeline progress boosts rare disease stock - Investing.com
Ultragenyx posts trial data backing Phase 3 design for Angelman syndrome therapy - MSN
Ultragenyx Pharmaceutical (NASDAQ:RARE) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
Ultragenyx: Ready For More Growth After Q3 Earnings Beat (NASDAQ:RARE) - Seeking Alpha
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Research Analysts Offer Predictions for RARE FY2024 Earnings - MarketBeat
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates - MSN
Ultragenyx posts data for Angelman syndrome therapy (RARE:NASDAQ) - Seeking Alpha
Ultragenyx Presents Positive Update on GTX-102 Angelman - GlobeNewswire
Ultragenyx's Angelman Treatment Shows 80% Patient Improvement in Phase 1/2 Trial | RARE Stock News - StockTitan
What is Wedbush's Estimate for RARE FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Negative Outlook of RARE FY2024 Earnings - MarketBeat
What is HC Wainwright's Estimate for RARE FY2024 Earnings? - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Estimate for RARE Q1 Earnings? - MarketBeat
Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - MarketBeat
Ultragenyx Pharma stock target raised, retains buy on strong revenue growth - Investing.com India
HC Wainwright Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $95.00 - MarketBeat
Ultragenyx Pharma stock target raised, retains buy on strong revenue growth By Investing.com - Investing.com South Africa
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts - Benzinga
International Assets Investment Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx: Excellent Company, Lackluster Stock (NASDAQ:RARE) - Seeking Alpha
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... - Yahoo Finance
Ultragenyx Reports Strong Q3 Growth and Milestones - TipRanks
Ultragenyx Pharmaceutical reports an over 40% increase in Q3 revenue - North Bay Business Journal
Ultragenyx Pharmaceutical Q3 2024 Earnings Preview - MSN
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings: Revenue S - GuruFocus.com
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Ultragenyx: Q3 Earnings Snapshot - San Francisco Chronicle
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update - The Manila Times
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast - Benzinga
Trend Tracker for (RARE) - Stock Traders Daily
Emerald Advisers LLC Raises Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
abrdn plc Sells 31,441 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? - Insider Monkey
Oversold Conditions For Ultragenyx Pharmaceutical (RARE) - Nasdaq
Pinnacle Associates Ltd. Has $6.63 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday - MarketBeat
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update - The Manila Times
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):